Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of XKH004 in moderate to severe active ankylosing spondylitis
CTR20232310Phase 3Completed
- Sponsor
- Kanova
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lzm012 in ankylosing spondylitis (AS), sponsored by Kanova. Started Sep 2023; status: completed.
02
Drugs
lzm012
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20232310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232310.